Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus

M. V. Betkerur, T. F. Yeh, K. Miller, R. J. Glasser, R. S. Pildes

Research output: Contribution to journalArticle

66 Citations (Scopus)


In the course of a double-blind trial of intravenous indomethacin therapy in premature infants with patent ductus arteriosus, renal function and urinary kallikrein were studied in 21 infants following one dose of either saline placebo or indomethacin. Ten infants were assigned to the control group and 11 were in the indomethacin group. Significantly lower urine output, fraction excretion of sodium, fraction excretion of chloride, and urinary kallikrein were noted by 45%, 59%, 63%, and 51%, respectively, in the indomethacin group as compared to the control group. There was a concomitant decrease in serum sodium concentration (P<.05) at 24 hours following indomethacin therapy. No significant difference in glomerular filtration rate was seen between the control group and the indomethacin-treated infants.

Original languageEnglish
Pages (from-to)99-102
Number of pages4
Issue number1
Publication statusPublished - Nov 9 1981
Externally publishedYes


ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this